DepoMed Inc. (DEPO) Tops Views

DepoMed Inc. (DEPO) shares are up $0.65 to $21.15 in after-hours trading Monday after the company reported its fourth quarter earnings results.

The Newark, Calif.-based pharmaceutical firm reported non-GAAP earnings of $0.21 per share on revenues of $194.6 million, up 379.20% from a year ago. Analysts were expecting EPS of $0.07 on revenues of $43.24 million.

For full year 2014, revenues came in at 390.4 million. On a GAAP basis, full year EPS was $2.05 vs. a non-GAAP of $0.26.

On valuation measures, DepoMed Inc. shares, which currently have an average 3-month trading volume of 923,774 shares, trade at a trailing-12 P/E of 15.73, a forward P/E of 52.56 and a P/E to growth ratio of 6.57. The median Wall Street price target on the name is $24.00 with a high target of $26.00. Currently ticker boasts 3 ‘Buy’ endorsements, compared to 0 ’Holds’ and no ‘Sell’.

Profitability-wise, DEPO has a t-12 profit and operating margin of 33.40% and 38.11%, respectively. The $1.20 billion market cap company reported $566.40 million in cash vs. $226.77 million in debt in its most recent quarter.

DEPO currently prints a one year return of about 56% ,and a year-to-date return of around 25%.

The chart below shows where the equity has traded over the last 52 weeks.

DepoMed Inc. is a specialty pharmaceutical company focused on pain and neurology. The firm was founded in 1995 and is headquartered in Newark, California.

Create Content With AI

Try TradingView For Free

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.